» Articles » PMID: 32229503

Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2020 Apr 2
PMID 32229503
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Diffuse intrinsic pontine glioma (DIPG) is an invariably fatal brain tumor occurring predominantly in children. Up to 90% of pediatric DIPGs harbor a somatic heterozygous mutation resulting in the replacement of lysine 27 with methionine (K27M) in genes encoding histone H3.3 (H3F3A, 65%) or H3.1 (HIST1H3B, 25%). Several studies have also identified recurrent truncating mutations in the gene encoding protein phosphatase 1D, , in 9%-23% of DIPGs. Here, we sought to investigate the therapeutic potential of targeting PPM1D, alone or in combination with inhibitors targeting specific components of DNA damage response pathways in patient-derived DIPG cell lines. We found that GSK2830371, an allosteric PPM1D inhibitor, suppressed the proliferation of -mutant, but not wild-type DIPG cells. We further observed that PPM1D inhibition sensitized -mutant DIPG cells to PARP inhibitor (PARPi) treatment. Mechanistically, combined PPM1D and PARP inhibition show synergistic effects on suppressing a p53-dependent RAD51 expression and the formation of RAD51 nuclear foci, possibly leading to impaired homologous recombination (HR)-mediated DNA repair in -mutant DIPG cells. Collectively, our findings reveal the potential role of the PPM1D-p53 signaling axis in the regulation of HR-mediated DNA repair and provide preclinical evidence demonstrating that combined inhibition of PPM1D and PARP1/2 may be a promising therapeutic combination for targeting -mutant DIPG tumors. IMPLICATIONS: The findings support the use of PARPi in combination with PPM1D inhibition against -mutant DIPGs.

Citing Articles

The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models.

Furst L, Roussel E, Leung R, George A, Best S, Whittle J Biology (Basel). 2024; 13(6).

PMID: 38927304 PMC: 11200883. DOI: 10.3390/biology13060424.


Radiotherapy and radio-sensitization in H3 -mutated diffuse midline gliomas.

Liu C, Kuang S, Wu L, Cheng Q, Gong X, Wu J CNS Neurosci Ther. 2023; 29(7):1721-1737.

PMID: 37157237 PMC: 10324372. DOI: 10.1111/cns.14225.


Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.

Noon A, Galban S Neoplasia. 2023; 40:100899.

PMID: 37030112 PMC: 10119952. DOI: 10.1016/j.neo.2023.100899.


A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.

Liu G, Feng Y, Li J, Deng T, Yin A, Yan L EClinicalMedicine. 2022; 54:101767.

PMID: 36583171 PMC: 9793276. DOI: 10.1016/j.eclinm.2022.101767.


Advances on Epigenetic Drugs for Pediatric Brain Tumors.

Skouras P, Markouli M, Strepkos D, Piperi C Curr Neuropharmacol. 2022; 21(7):1519-1535.

PMID: 36154607 PMC: 10472812. DOI: 10.2174/1570159X20666220922150456.